{{medical}}
{{drugbox |
| type = mab
| image =
| source = [[人類|人類]]
| target = [[CD11a|CD11a]]
<!--Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 214745-43-4
| ATC_prefix = L04
| ATC_suffix = AA21
| ATC_supplemental = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00095
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XX2MN88N5D
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201575
| chemical_formula = 
| molecular_weight = 
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| pregnancy_category = 
| legal_status = 
| routes_of_administration = 
}}
'''依法利珠单抗'''（{{lang|en|'''Efalizumab'''}}，藥品商品名為 '''Raptiva'''，瑞體膚，[[默克|默克]]）是[[牛皮癬|牛皮癬]]的治療用藥，是一種抗[[CD11a|CD11a]]的單株抗體製劑，其作用機制是辨識白血球上的CD11a抗原，使白血球與其他細胞附著的能力降低，抑制其免疫作用。

因為依法利珠单抗會抑制[[免疫系統|免疫系統]]，所以其引發的副作用包括細菌性[[敗血症|敗血症]]、病毒性[[腦膜炎|腦膜炎]]，真菌性疾病，或因再活化的潛伏性[[JC病毒|JC病毒]]引發[[漸進性多病灶腦白質病|漸進性多病灶腦白質病]](Progressive multifocal leukoencephalopathy, PML)。 <ref name="urlEfalizumab FDA Warning">{{cite web |url=http://www.medpagetoday.com/InfectiousDisease/PublicHealth/11358|title=Efalizumab FDA Warning|format= |work= |accessdate=2008-12-07}}</ref> 

因為此藥有產生漸進性多病灶腦白質病的風險，[[歐洲藥品管理局|歐洲藥品管理局]](European Medicines Agency)於2009年2月提議，應暫停依法利珠单抗在[[歐盟|歐盟]]販售。<ref name="urlEMEA suspension press release">{{cite web|url=http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf |title=EMEA press release regarding suspension |format=PDF |work= |accessdate=2009-02-20 |deadurl=yes |archiveurl=https://web.archive.org/web/20091226101218/http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf |archivedate=2009-12-26 }}</ref>

== 參考資料 ==
{{reflist}}
{{免疫抑制剂}}
[[Category:重组蛋白|Category:重组蛋白]]
[[Category:免疫抑制剂|Category:免疫抑制剂]]
[[Category:撤回药物|Category:撤回药物]]